Financial Summary for the Fiscal Year Ending March 2026 [IFRS] (Consolidated)

Overview of Business Performance

For the fiscal year ending March 2026, consolidated net sales decreased by 0.2% to 161.688 billion yen. Operating loss was 18.592 billion yen (compared to a profit of 9.428 billion yen in the previous year), net loss was 10.553 billion yen (compared to a profit of 7.896 billion yen), and net loss attributable to owners of the parent was 10.693 billion yen. The main factors include delayed recovery in demand for vinylidene fluoride resin due to slowdown in the EV market, and impairments related to manufacturing equipment for chronic kidney disease drugs due to drug price reductions. Segment-wise, the Functional Products and Chemical Products segments saw revenue and profit increases, while the Resin Products segment experienced decreases in both.

Financial Position and Dividend Status

Total assets as of the end of March 2026 decreased by 33.844 billion yen to 338.444 billion yen, while cash and cash equivalents increased by 29.726 billion yen to 29.726 billion yen. The company repurchased treasury shares worth 39.057 billion yen and paid dividends totaling 6.341 billion yen. The dividend policy targets a dividend payout ratio (DOE) of approximately 5%, with an expected annual dividend of 216 yen per share (mid-term 108 yen, year-end 108 yen) for the fiscal year 2026.